Youssef Rddad

Seattle

Staff Writer at Oncology News Central

Journalist, composer, @theadvocatebr, @arkansasonline and @AP alumn.

Featured in: Favicon

theadvocate.com Favicon

msn.com

foxnews.com Favicon

washingtonpost.com Favicon

time.com

latimes.com Favicon

sfgate.com Favicon

usnews.com Favicon

yahoo.com (+1) Favicon

apnews.com + 111 more

Articles

Fallout From Failed Phase 3 Trial: Adjuvant Therapy “Not the Most Appropriate Option” for All Stage III Melanomas

3 weeks ago | oncologynewscentral.com | Youssef Rddad

Although the combination of nivolumab and relatlimab failed to meet its primary endpoint in the randomized, double-blind, phase 3 RELATIVITY-098 clinical trial, findings may still provide broader insights about adjuvant approaches in melanoma, experts suggest. Results of the study were presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (LBA9500).
Myeloma Quadruplet Doubles Sustained MRD Negativity in Transplant-Eligible Patients

3 weeks ago | oncologynewscentral.com | Youssef Rddad

A subcutaneous daratumumab-based quadruplet regimen significantly improved sustained minimal residual disease (MRD) negativity and progression-free survival (PFS) in transplant-eligible patients with newly diagnosed multiple myeloma, according to results presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 7501).
ctDNA-MRD Should Be “Standard Component” of DLBCL Assessment, Data Suggest

3 weeks ago | oncologynewscentral.com | Youssef Rddad

A prospective analysis demonstrated the prognostic significance of circulating tumor DNA (ctDNA) measurable residual disease (MRD) detection, using phased variant enrichment and detection sequencing(PhasED-Seq) in patients with diffuse large B-cell lymphoma (DLBCL) receiving first-line therapy.
New Standard of Care in Triple-Negative Breast Cancer?

4 weeks ago | oncologynewscentral.com | Youssef Rddad

Sacituzumab govitecan (SG; Trodelvy) plus pembrolizumab (Keytruda) significantly prolonged progression-free survival (PFS) compared with chemotherapy plus pembrolizumab in patients with previously untreated, PD-L1-positive advanced triple-negative breast cancer (TNBC). The findings were based on the results from the phase 3 ASCENT-04/KEYNOTE-D19 clinical trial, which were presented as part of the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (LBA109).
Practice Change in Advanced Colorectal Cancer: Combination Outperforms Chemo for Survival

4 weeks ago | oncologynewscentral.com | Youssef Rddad

First-line encorafenib (Braftovi), cetuximab (Erbitux), and mFOLFOX6 (EC+mFOLFOX6) significantly improved progression-free survival (PFS) and overall survival (OS) compared with standard chemotherapy in patients with BRAF V600E-mutated metastatic colorectal cancer. The findings were presented as part of the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (LBA 3500) and were based on results from the phase 3 BREAKWATER clinical trial.
First Studies Reported Ahead of 2025 ASCO Annual Meeting

1 month ago | oncologynewscentral.com | Youssef Rddad

Advances in treating certain lung and breast cancers, an artificial intelligence tool that helps identify HER2 status, and the potential for GLP-1 agonists to lower cancer risks were among the studies highlighted at the first news conference ahead of the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. This year’s conference runs from May 30 to June 3 in Chicago and will feature more than 6,000 abstracts, including practice-changing data across multiple diseases.
Emerging Data Challenge Current Breast Cancer Treatment Algorithms

1 month ago | oncologynewscentral.com | Youssef Rddad

Emerging data suggest that liquid biopsy and circulating tumor DNA (ctDNA) monitoring could soon reshape treatment paradigms for clinicians managing hormone receptor–positive, ESR1-mutated breast cancer. Although traditional approaches rely on clinical signs of progression, new studies indicate that early detection of ESR1 mutations may allow for proactive therapeutic shifts before disease progression.
Trispecifics and Bispecific Combos Poised to Transform Myeloma Care?

1 month ago | oncologynewscentral.com | Youssef Rddad

Recent research in multiple myeloma, along with data set to be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting,may soon transform clinical practice in multiple myeloma, experts say. The most closely watched developments include studies examining bispecific antibody combinations, new CAR-T therapy targets, and early data on trispecific antibodies.
Without Key Data, Expanded Treatment Options Complicate Gastric Cancer Care

1 month ago | oncologynewscentral.com | Youssef Rddad

For clinicians treating patients with HER2-negative gastric and gastroesophageal junction (GEJ) cancers, immune checkpoint inhibitors and claudin 18.2–targeted therapies have expanded biomarker-driven options. However, when both treatments are viable choices, decision-making can be challenging.
FDA Approves Retifanlimab (Zynyz) for Advanced Anal Cancer

1 month ago | oncologynewscentral.com | Youssef Rddad

On May 15, the U.S. Food and Drug Administration (FDA) approved frontline retifanlimab-dlwr (Zynyz) plus platinum-based chemotherapy for adults with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC). The agency also approved retifanlimab as monotherapy for adults with locally recurrent or metastatic SCAC with disease progression on or intolerance to platinum-based chemotherapy.